HomeInsightsStock Comparison

Biocon Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Biocon Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 04, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 318.65 as of 02 May 15:30.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 31 on March 2024 . This represents a CAGR of -6.51% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 7.1 on March 2020 to 30.2 on March 2024 . This represents a CAGR of 33.58% over 5 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 31707 crore on March 2024 . This represents a CAGR of -0.48% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 225.6 crore on March 2020 to ₹ 1507 crore on March 2024 . This represents a CAGR of 46.21% over 5 years.
  • The revenue of Biocon Ltd for the Dec '24 is ₹ 3874 crore as compare to the Sep '24 revenue of ₹ 3648 crore. This represent the growth of 6.18% The revenue of SMS Pharmaceuticals Ltd for the Dec '24 is ₹ 175.48 crore as compare to the Sep '24 revenue of ₹ 198.05 crore. This represent the decline of -11.4%.
  • The ebitda of Biocon Ltd for the Dec '24 is ₹ 804.7 crore as compare to the Sep '24 ebitda of ₹ 743.9 crore. This represent the growth of 8.17% The ebitda of SMS Pharmaceuticals Ltd for the Dec '24 is ₹ 35.34 crore as compare to the Sep '24 ebitda of ₹ 32.77 crore. This represent the growth of 7.84%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 81.1 crore over 7 quarters. This represents a CAGR of -29.33% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 8.81 crore to ₹ 17.08 crore over 7 quarters. This represents a CAGR of 45.98% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 50.32 % on March 2024 . This represents a CAGR of -10.30% over 3 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 6.48 % on March 2020 to 6.86 % on March 2024 . This represents a CAGR of 1.15% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About SMS Pharmaceuticals Ltd

  • SMS Pharmaceuticals Limited was incorporated in December, 1987.
  • The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
  • Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh.
  • Its business activity is a single primary business segment of 'Bulk Drugs'. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs.

Biocon Ltd News Hub

News

Biocon's board OKs to raise Rs 4,500-cr

'Raising of funds by way of issuance any instrument or security, including equity shares, ...

Read more

24 Apr 2025 08:11

News

Board of Biocon approves fund raising up to Rs 4,500 cr

The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up ...

Read more

23 Apr 2025 20:05

News

Biocon to consider fund Raising

Biocon will hold a meeting of the Board of Directors of the Company on 23 April 2025. Powe...

Read more

21 Apr 2025 09:37

News

Biocon surges on U.S. deal for Eylea copycat drug

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating...

Read more

15 Apr 2025 09:58

News

Board of Biocon approves CP issuance of Rs 600 cr

The Board of Biocon at its meeting held on 04 April 2025 has approved issuance of Commerci...

Read more

05 Apr 2025 14:34

News

Biocon to table results

Biocon will hold a meeting of the Board of Directors of the Company on 8 May 2025. Powered...

Read more

03 Apr 2025 09:49

SMS Pharmaceuticals Ltd News Hub

News

SMS Pharmaceuticals' Unit VII receives WHO Geneva prequalification

SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhr...

Read more

02 May 2025 12:36

News

SMS Pharma gains after Hyderabad facility completes USFDA inspection

According to an exchange filing, the inspection was conducted from 17 March to 21 March 20...

Read more

24 Mar 2025 09:59

News

SMS Pharma's Hyderabad facility completes USFDA inspection with 1 observation

According to an exchange filing, the inspection was conducted from 17 March to 21 March 20...

Read more

22 Mar 2025 16:28

News

SMS Pharmaceuticals schedules board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 Feb...

Read more

06 Feb 2025 16:50

News

SMS Pharmaceuticals to convene board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 Nove...

Read more

02 Nov 2024 12:49

News

SMS Pharmaceuticals to conduct AGM

SMS Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be...

Read more

08 Aug 2024 14:06

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of SMS Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for SMS Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Biocon Ltd or SMS Pharmaceuticals Ltd?

Market cap of Biocon Ltd is 38,257 Cr while Market cap of SMS Pharmaceuticals Ltd is 2,123 Cr

What are the key factors driving the stock performance of Biocon Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Biocon Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and SMS Pharmaceuticals Ltd?

As of May 4, 2025, the Biocon Ltd stock price is INR ₹318.65. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹239.55.

How do dividend payouts of Biocon Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Biocon Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions